The combination of 6-MF and immunotherapy reduced melanoma proliferative capacity, increased intracellular oxidative stress, and promoted, phosphorylation to inhibit the SLC7A11/GPX4 signaling pathway and promote ferroptosis in melanoma cells. The gene discussed is SLC7A11; the disease is melanoma.